ライフサイエンスコーパス: T-lymphocyte count

1 his effect differs depending on CD4-positive T-lymphocyte count.

2 elation of these changes with overall CD4(+) T lymphocyte counts.

3 outgrowth patterns and inversely with CD4(+) T lymphocyte counts.

4 in CrAg-negative patients with similar CD4+ T-lymphocyte counts.

5 d undetectable viral loads and intact CD4(+) T-lymphocyte counts.

6 sma HIV-1 viral load and increases in CD4(+) T-lymphocyte counts.

7 d in 267 (15%) of 1748 patients (median CD4+ T-lymphocyte count, 242 per cubic millimeter; interquart

8 igher weight, serum albumin levels, and CD4+ T-lymphocyte counts (492 +/- 828 cells/mm3 versus 57 +/-

9 o the immunologic parameters of blood CD4(+) T lymphocyte count and breadth of the HIV-1-specific CTL

10 hazards models revealed that both the total T lymphocyte count and CD8 T lymphocyte count provided i

11 The mean+/-SEM CD4(+) T lymphocyte count and virus load for all patients were

12 CD4 T lymphocyte counts and all virologic parameters examine

13 herapy regimens can increase circulating CD4 T lymphocyte counts and decrease the risk of opportunist

14 icantly associated with higher activated CD8 T lymphocyte counts and higher viral load levels.

15 s group of patients with relatively high CD4 T lymphocyte counts and low measures of virus load at ba

16 tions describing the general trajectories of T lymphocyte counts and percentages of the Dutch populat

17 characteristic pattern of low CD4+ and CD8+ T-lymphocyte counts and low CD5+ B-lymphocyte counts.

18 Serum CD4(+) T-lymphocyte counts and SIV copy numbers did not differ

19 of these measures and current or nadir CD4+ T-lymphocyte counts, and each measure was compared betwe

20 tive (PPD) tuberculin and mumps antigen, CD4 T-lymphocyte counts, and frequency of tuberculosis.

21 donor with a low viral burden, stable CD4(+) T-lymphocyte counts, and little evidence of CD8(+) T-cel

22 CD4 + T-lymphocyte counts are used to assess CD4 + decline and

23 tive increase in the peripheral blood CD4(+) T-lymphocyte count as compared with that of nonsmokers.

24 abundant thymic tissue had higher naive CD4+ T lymphocyte counts at weeks 2-24 after therapy than ind

25 he heralding manifestation of AIDS, high CD4 T-lymphocyte count at disease onset, lesion enhancement

26 Immunity was assessed by CD4 T-lymphocyte counts at AIDS onset.

27 The animal had declining CD4+ T-lymphocyte counts at the time of the LN biopsy.

28 remia coincided with recovery of normal CD8+ T lymphocyte counts between days 48 and 76.

29 ns of IP-10/CXCL10, whereas CD4(+)/HLA-DR(+) T lymphocyte counts correlated positively with serum con

30 Activated CD4(+)/CD25(+) T-lymphocyte counts correlated negatively with serum con

31 A CD4 T-lymphocyte count determines eligibility for antiretrov

32 Low CD4+ T-lymphocyte count, disease stage, performance status, s

33 CD4(+) T lymphocyte counts, eosinophil counts, and plasma HIV-1

34 B-lymphocyte and specific cytokine-producing T-lymphocyte counts following the second, third, and fou

35 ycin sulfate, and among patients with a CD4+ T-lymphocyte count greater than 0.200 x 10(9)/L (200/mic

36 h an HIV-1 RNA load <50 copies/mL and CD4(+) T lymphocyte count >400 cells/mm(3) were randomized to u

37 lex [MAC] infection) in persons whose CD4(+) T lymphocyte counts had increased by >/=100 cells/microL

38 1); (2) HIV-infected individuals whose CD4+ T-lymphocyte counts had always been more than 200/microL

39 dary OI prophylaxis among persons whose CD4+ T lymphocyte counts have increased in response to antire

40 therapy and level of immunodeficiency (CD4+ T lymphocyte count, human immunodeficiency virus [HIV] R

41 es, as demonstrated by an increase in CD4(+) T-lymphocyte counts in recent clinical trials.

42 ociated with reduced increases in the CD4(+) T lymphocyte count, irrespective of plasma HIV RNA level

43 ART) is recommended when the absolute CD4(+) T lymphocyte count is <200 cells/mm(3), and it should be

44 additional boosters, while antigen-specific T-lymphocyte counts maintained a consistently high level

45 e Hospital, London, who had at least one CD4 T lymphocyte count of < 5 cells/mm3 (n = 166) were prosp

46 ntiretroviral-naive patients with a mean CD4 T lymphocyte count of 659 cells/microliter at baseline a

47 s to 55 HIV-1-infected individuals with CD4+ T lymphocyte counts of 50-500 cells/microL.

48 NA values of 50 copies/mL or fewer and a CD4 T-lymphocyte count of 100 cells/mL or greater or patient

49 related pulmonary complications, with a CD4+ T-lymphocyte count of 331.6 +/- 62.1 (mean +/- SEM).

50 ents with untreated HIV infection with a CD4 T-lymphocyte count of 500 cells/mL or greater.

51 -infected individuals with a history of CD4+ T-lymphocyte counts of less than 50/microL, but with cur

52 changes in their total T lymphocyte and CD8 T lymphocyte counts over time.

53 ; P < .001); and larger CRAE with lower CD4+ T lymphocyte count (P = .04).

54 pillomavirus infection (p=0.0013), lower CD4 T lymphocyte count (p = 0.0395), and history of frequent

55 (P = 0.018) and increases in peripheral CD4 T lymphocyte counts (P < 0.01).

56 with baseline CD4+, CD4+CD28+, and CD8+CD28+ T lymphocyte counts (P<.05) and inversely correlated wit

57 low hemoglobin (p = 0.11), and CD4-positive T-lymphocyte count (p = 0.04).

58 se who developed tuberculosis had lower CD4+ T-lymphocyte counts (P = 0.02) and were more likely to b

59 Among the 134 patients with CD4 T-lymphocyte counts performed within 3 months of Cryptos

60 at both the total T lymphocyte count and CD8 T lymphocyte count provided important prognostic informa

61 retions were negatively correlated with CD4+ T lymphocyte count (r=-0.44, P<.01 and r=-0.40, P<.01, r

62 s correlated significantly with current CD4+ T-lymphocyte count (r = - 0.344, P = 0.022).

63 n-significant S1-specific cytokine-producing T-lymphocyte counts (range 0.5-1.3-fold).

64 during the peak of viremia, the milk CD4(+) T lymphocyte counts remained unchanged, despite active v

65 ee subgroups based on current and nadir CD4+ T-lymphocyte counts (severely immunosuppressed, immune r

66 are more likely to present with lower CD4(+) T-lymphocyte counts than MSM who do not attend church.

67 Patients in groups 1 and 2 had CD4+ T-lymphocyte counts that were similar to those in patien

68 CD4+ T lymphocyte counts, time to first HIV-1 disease progres

69 e-art HIV diagnostic technologies for CD4(+) T lymphocyte count, viral load measurement, and drug res

70 The mean (SD) age was 35 (6.9) years, CD4 T-lymphocyte count was 236 (139) and log10 plasma HIV RN

71 ral load of <400 copies/mL), and median CD4+ T-lymphocyte count was 459 cells/mm(3) (interquartile ra

72 oad of <400 copies/mL, and the median CD4(+) T-lymphocyte count was 471 cells/microL.

73 In this group, CD4+ T-lymphocyte count was low, despite a significantly lowe

74 s were incidentally found to have low CD4(+) T-lymphocyte counts, we investigated whether plateletphe

75 viral load and sustained decreases in CD4(+) T lymphocyte count were observed, especially in subjects

76 CD4(+) T-lymphocyte counts were <200 cells per microliter in 0/

77 Current and nadir (lowest previous) CD4+ T-lymphocyte counts were identified for each subject.

78 donors, respectively (P = .019), and CD8(+) T-lymphocyte counts were low in 0/20, 4/20, and 11/20 do

79 CD4 T-lymphocyte counts were substantially higher in the lon

80 greater virologic suppression and higher CD4 T-lymphocyte counts when managed by a multidisciplinary